These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 33766649)

  • 1. Current paradigms in epigenetic anticancer therapeutics and future challenges.
    Singh M; Kumar V; Sehrawat N; Yadav M; Chaudhary M; Upadhyay SK; Kumar S; Sharma V; Kumar S; Dilbaghi N; Sharma AK
    Semin Cancer Biol; 2022 Aug; 83():422-440. PubMed ID: 33766649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation.
    Chistiakov DA; Orekhov AN; Bobryshev YV
    Int J Cardiol; 2017 Jan; 227():66-82. PubMed ID: 27852009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting epigenetic regulation for cancer therapy using small molecule inhibitors.
    Kumar A; Emdad L; Fisher PB; Das SK
    Adv Cancer Res; 2023; 158():73-161. PubMed ID: 36990539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promises and challenges of anticancer drugs that target the epigenome.
    Verbrugge I; Johnstone RW; Bots M
    Epigenomics; 2011 Oct; 3(5):547-65. PubMed ID: 22126246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
    Valdespino-Gómez VM; Valdespino-Castillo VE
    Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements.
    Singh D; Khan MA; Siddique HR
    Epigenomics; 2023 Apr; 15(8):517-537. PubMed ID: 37313832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
    Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
    Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic-based therapies in cancer: progress to date.
    Song SH; Han SW; Bang YJ
    Drugs; 2011 Dec; 71(18):2391-403. PubMed ID: 22141383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer.
    Gutiérrez JR; Salgado ARM; Arias MÁ; San-Juan-Vergara H; Rada WR; Gómez CMM
    Curr Med Chem; 2022; 29(9):1503-1542. PubMed ID: 34963430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the cancer epigenome for therapy.
    Jones PA; Issa JP; Baylin S
    Nat Rev Genet; 2016 Sep; 17(10):630-41. PubMed ID: 27629931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic regulation and cancer (review).
    Chen QW; Zhu XY; Li YY; Meng ZQ
    Oncol Rep; 2014 Feb; 31(2):523-32. PubMed ID: 24337819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
    Jazirehi AR
    Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting epigenetic networks with polypharmacology: a new avenue to tackle cancer.
    Franci G; Miceli M; Altucci L
    Epigenomics; 2010 Dec; 2(6):731-42. PubMed ID: 22122079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human DNA (cytosine-5)-methyltransferases: a functional and structural perspective for epigenetic cancer therapy.
    Rondelet G; Wouters J
    Biochimie; 2017 Aug; 139():137-147. PubMed ID: 28600135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic regulation of gene expression as an anticancer drug target.
    Ferguson LR; Tatham AL; Lin Z; Denny WA
    Curr Cancer Drug Targets; 2011 Feb; 11(2):199-212. PubMed ID: 21158714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic therapies in patients with solid tumors: Focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors.
    Katarzyna R; Lucyna B
    J Cancer Res Ther; 2019; 15(5):961-970. PubMed ID: 31603095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The promise and failures of epigenetic therapies for cancer treatment.
    Bojang P; Ramos KS
    Cancer Treat Rev; 2014 Feb; 40(1):153-69. PubMed ID: 23831234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.